SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms
Khrystyna Ryabenko, Valérie Schini-Kerth, Patrick Ohlmann, Elena Galli · 2026
Read SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms by Khrystyna Ryabenko, Valérie Schini-Kerth, Patrick Ohlmann, Elena Galli (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13297162.txt.
Description
Khrystyna Ryabenko and colleagues review whether diabetes drugs called SGLT2 inhibitors could modify hypertrophic cardiomyopathy in a 2026 article. This inherited heart-muscle thickening is driven at first by gene faults, yet oxidative stress and faulty energy handling push it forward. No current therapy targets those secondary drivers well.
The drugs protect failing hearts even without diabetes, through several routes the review details. They ease oxidative stress, improve mitochondrial function, restore sodium and calcium balance, and quiet inflammation. Early laboratory and translational findings fit the heart condition's known weak points. The authors build a mechanistic case for trials, while the evidence remains short of patient proof.
Catalog record
| CREATOR | Khrystyna Ryabenko, Valérie Schini-Kerth, Patrick Ohlmann, Elena Galli |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |